- Home
- NMRK vs VRDN Comparison
NMRK vs VRDN Comparison
Compare NMRK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | VRDN |
|---|---|---|
| Founded | 1929 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NMRK | VRDN |
|---|---|---|
| Price | $14.23 | $28.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $18.80 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $3,294,024,000.00 | $5,706,000.00 |
| Revenue This Year | $13.05 | $13.90 |
| Revenue Next Year | $7.68 | $284.55 |
| P/E Ratio | $21.58 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $9.65 | $9.90 |
| 52 Week High | $19.84 | $34.29 |
Technical Indicators
Market Signals| Indicator | NMRK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 42.79 |
| Support Level | $13.36 | $26.31 |
| Resistance Level | $18.00 | $33.71 |
| Average True Range (ATR) | 0.64 | 1.58 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 31.63 | 46.21 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).